16.04.2026

Egnach, April 16, 2026 – Resaphene Suisse AG is expanding the strategic positioning of its tinniwell in-ears and is thereby creating the basis for significantly increased sales potential.

In the future, the tinniwell in-ears will be increasingly positioned as an over-the-counter product (OTC – without a doctor's prescription). The aim is to make the product accessible to a broader target group beyond its previous use for tinnitus. The focus is on targeted heat application in the ear area, which can help promote relaxation and general well-being. This opens up additional everyday uses, especially for:

• Stress-related tension

• Inner restlessness

• Sleep problems (e.g. difficulty falling asleep)

• Concentration problems

• Feelings of pressure and tension in the head and ear area

The application is deliberately intended as a supportive measure and does not replace medical treatment. An essential part of the new strategy is also independence from the app:

The tinniwell in-ears can in future be used and distributed independently. This reduces barriers to use for end customers and at the same time simplifies access to new sales channels. Through this realignment, Resaphene Suisse AG is opening up additional market segments in the areas of well-being and everyday applications. At the same time, the OTC positioning enables simplified marketing via digital channels, direct sales, and traditional retail. With this strategic expansion, the company aims to significantly increase the reach of tinniwell and sustainably support further growth.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015 and has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG

Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 71 510 07 24
a.rauterkus@resaphene.ch